The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

Most countries involved in FDA drug-approval trials do not receive timely market authorization for the studied drugs.

Premature mortality increased among adults in the US between 2012 and 2022, particularly among Black individuals.

A large percentage of US adults report feelings of loneliness and isolation, with societal division intensifying these feelings.

Fibromyalgia severity scores showed modest seasonal variations, with higher widespread pain reported during autumn vs summer.